Clinical Trial Update: GVH 022P: Study Using Anti Tumor Necrosis Factor Antibody (Infliximab) for Treatment of Acute Graft Versus Host Disease [Phase 1]

View source ↗

Summary

Phase 1 study evaluating infliximab for acute graft-versus-host disease has been completed. The trial explored the anti-TNF antibody as a treatment option for G…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Infliximab (infliximab)

Snippet

Sponsor: Emory University | Conditions: Graft vs Host Disease | Phase 1 | Status: COMPLETED